FORWARD PHARMA A/S-ADR (FWP) Stock Price, Forecast & Analysis
USA - NASDAQ:FWP - US34986J2042 - ADR
FWP Key Statistics, Chart & Performance
The current stock price of FWP is 1.95 USD. In the past month the price decreased by -35%. In the past year, price decreased by -67.34%.
FWP Latest News, Press Relases and Analysis
FWP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About FWP
Company Profile
Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. The firm granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The firm has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
Company Info
FORWARD PHARMA A/S-ADR
Oestergade 24A, 1, Copenhagen K
COPENHAGEN 1100 DK
CEO: Claus Bo Svendsen
Employees: 4
Phone: 4533444242.0
FORWARD PHARMA A/S-ADR / FWP FAQ
What does FWP do?
Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. The firm granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The firm has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
What is the current price of FWP stock?
The current stock price of FWP is 1.95 USD. The price increased by 7.73% in the last trading session.
Does FWP stock pay dividends?
FWP does not pay a dividend.
What is the ChartMill technical and fundamental rating of FWP stock?
FWP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does FORWARD PHARMA A/S-ADR have?
FORWARD PHARMA A/S-ADR (FWP) currently has 4 employees.
FWP Technical Analysis
FWP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FWP. While FWP has a great health rating, there are worries on its profitability.
FWP Financial Highlights
Over the last trailing twelve months FWP reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 71.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |